Amedisys (NASDAQ:AMED) Given New $100.00 Price Target at Royal Bank of Canada

Amedisys (NASDAQ:AMEDGet Free Report) had its target price increased by research analysts at Royal Bank of Canada from $97.00 to $100.00 in a report issued on Monday, Benzinga reports. The firm currently has an “outperform” rating on the health services provider’s stock. Royal Bank of Canada’s target price suggests a potential upside of 8.52% from the stock’s current price.

Separately, started coverage on Amedisys in a research report on Saturday. They issued a “buy” rating on the stock. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from, Amedisys has an average rating of “Hold” and an average price target of $97.50.

View Our Latest Research Report on AMED

Amedisys Stock Performance

Shares of AMED opened at $92.15 on Monday. The company has a quick ratio of 1.05, a current ratio of 1.05 and a debt-to-equity ratio of 0.32. The business’s 50 day moving average price is $93.76 and its 200-day moving average price is $93.62. Amedisys has a 52 week low of $69.36 and a 52 week high of $96.44. The stock has a market cap of $3.01 billion, a P/E ratio of -297.26, a P/E/G ratio of 4.34 and a beta of 0.86.

Amedisys (NASDAQ:AMEDGet Free Report) last released its quarterly earnings data on Wednesday, February 21st. The health services provider reported $0.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by ($0.10). The business had revenue of $570.79 million during the quarter, compared to the consensus estimate of $566.85 million. Amedisys had a negative net margin of 0.44% and a positive return on equity of 12.76%. The business’s revenue was up 1.6% compared to the same quarter last year. During the same period last year, the company posted $1.16 earnings per share. Equities research analysts anticipate that Amedisys will post 4.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Amedisys

Hedge funds and other institutional investors have recently modified their holdings of the stock. Pinebridge Investments L.P. purchased a new stake in shares of Amedisys in the 2nd quarter worth $26,000. Covestor Ltd lifted its holdings in Amedisys by 88.9% in the 1st quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock worth $56,000 after purchasing an additional 152 shares in the last quarter. Lazard Asset Management LLC purchased a new position in Amedisys in the 1st quarter worth approximately $68,000. Neo Ivy Capital Management purchased a new position in Amedisys in the 2nd quarter worth approximately $44,000. Finally, KBC Group NV purchased a new position in Amedisys in the 4th quarter worth approximately $41,000. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

About Amedisys

(Get Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

See Also

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with's FREE daily email newsletter.